Single-Dose Intranasal Treatment with DEF201 (Adenovirus Vectored Consensus Interferon) Prevents Lethal Disease Due to Rift Valley Fever Virus Challenge

@inproceedings{Gowen2014SingleDoseIT,
  title={Single-Dose Intranasal Treatment with DEF201 (Adenovirus Vectored Consensus Interferon) Prevents Lethal Disease Due to Rift Valley Fever Virus Challenge},
  author={Brian B. Gowen and Jane Ennis and Kevin W. Bailey and Zachary G Vest and Dionna Scharton and Eric J. Sefing and Jeffrey D. Turner},
  booktitle={Viruses},
  year={2014}
}
Rift Valley fever virus (RVFV) causes severe disease in humans and ungulates. The virus can be transmitted by mosquitoes, direct contact with infected tissues or fluids, or aerosol, making it a significant biological threat for which there is no approved vaccine or therapeutic. Herein we describe the evaluation of DEF201, an adenovirus-vectored interferon alpha which addresses the limitations of recombinant interferon alpha protein (cost, short half-life), as a pre- and post-exposure treatment… CONTINUE READING
Highly Cited
This paper has 34 citations. REVIEW CITATIONS